Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1989-04-18
1991-01-01
Ford, John M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 18, A61K 31435, C07D41104
Patent
active
049818589
ABSTRACT:
The (+)-cis-, (-)-cis-, (+)-trans- and (-)-trans- forms of 2-methylspiro(1,3-oxathiolan-5,3')quinuclidine are prepared by optical resolution of each of the (.+-.)-cis- and (.+-.)-trans-isomers. These compounds find application in treating diseases of the central nervous system in mammals, especially diseases due to a deficiency in the central cholinergic system. Biological tests indicate that the (-)-cis-form, as well as the (.+-.)-cis-isomer, shows particular promise for treating senile dementia of Alzheimer's type.
REFERENCES:
patent: 4855290 (1989-08-01), Fisher et al.
Saunders et al., J. Med. Chem. 30: 969-975 (1987).
Watson et al., J. Pharm. Exp. Ther. 237: 411-418 (1986).
The Merck Index, 10th ed., Merck & Co., Inc. Rahway, N.J., (1983), Monograph No. 6328.
Fisher Abraham
Grunfeld Yona
Heidman Eliahu
Karton Ishal
Levy Aharon
Ford John M.
State of Israel, represented by the Prime Minister's Office, Isr
LandOfFree
Optical isomers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Optical isomers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Optical isomers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1996471